Efficiency of topical imiquimod 5% cream in the management of chronic radiation dermatitis with multiple neoplasias

European Journal of Dermatology

Volumn 16, Issue 1, 2006, Pages 56-58

  Sachse, Michael M ^a   Zimmermann, Jutta ^b   Bahmer, Friedrich A ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Hospital Bremen Mitte   (Germany)

Author keywords

Actinic keratoses; Basal cell carcinoma; Chronic radiation dermatitis; Imiquimod; Immune response modifier; Squamous cell carcinoma

Indexed keywords

IMIQUIMOD; IMMUNOMODULATING AGENT; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CASE REPORT; ERBIUM YAG LASER; EROSION; ERYTHEMA; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IONIZING RADIATION; MULTIPLE CANCER; RADIATION DERMATITIS; REMISSION; SKIN INFLAMMATION;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; RADIODERMATITIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 32344450053     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Peter RU. The cutaneous radiation syndrome. In: McVittie TJ, Weiss JF, Browne D, eds. Advances in the Treatment of Radiation Injuries. New York: Elsevier, 1990: 237-41.
2. Kawakami T, Saito R, Miyazaki S. Chronic radiodermatitis following repeated percutaneous transluminal coronary angioplasty. Br J Dermatol 1999; 141(1): 150-3.
3. Steinert M, Weiss M, Gottlober P, Belyi D, Gergel O, Bebeshko V, Nadejina N, Galstian I, Wagemaker G, Fliedner TM, Peter RU. Delayed effects of accidental cutaneous radiation exposure: fifteen years of follow-up after the Chernobyl accident. J Am Acad Dermatol 2003; 49(3): 417-23.
4. Rao J, Dekoven JG, Beatty JD, Jones G. Cutaneous angiosarcoma as a delayed complication of radiation therapy for carcinoma of the breast. J Am Acad Dermatol 2003; 49(3): 532-8.
5. Grassel R, Hornstein OP. Bowen carcinoma following many years' use of a "radium cushion" (author's transl). MMW Munch Med Wochenschr 1979; 121(22): 753-6.
6. Garland SM. Imiquimod. Curr Opin Infect Dis 2003; 16(2): 85-9.
7. Hengge UR, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg 2004; 30(8): 1101-12.
8. König A, Hoffmann R, Happle R. Radiation damage due to an asthma related application of a radium bandage (author's transl). Z Hautkr 1997; 72: 362-4.
9. Bahmer FA. Morphometry in Clinical Dermatology. In: Wilhelm KP, Elsner P, Berardesca E, Maibach HI, eds. Bioengineering of the skin: skin surface imaging and analysis. Boca Raton: CRC Press, 1997.
10. Cipollaro VA. Radiation dermatitis today. J Eur Acad Dermatol Venereol 2001; 15(4): 300-1.
11. Peter RU. Pathophysiologie kutaner Strahlenreaktionen. In: Peter RU, Plewig G. Strahlentherapie dermatologischer Erkrankungen. Blackwell, Berlin Wien, S7-24.
12. Braun-Falco O, Plewig G, Wolff HH. Hautkrankheiten durch ionisierende Strahlen. In: Braun-Falco O, Plewig G, Wolff HH, eds. Dermatologie und Venerologie. 4. Berlin, Heidelberg, New York: Auflage. Springer, 1995: S491-S492.
13. Camacho FM. Chronic radiation dermatitis: what's new in management? J Eur Acad Dermatol Venereol 2000; 14(4): 246-7.
14. Cerburkovas O, Krause M, Ulrich J, Bonnekoh B, Gollnick H. Disseminated actinic keratoses. Comparison of topical photodynamic therapy with 5-aminolevulinic acid and topical 5% imiquimod cream. Hautarzt 2001; 52(10 Pt 2): 942-6.
15. Lysa B, Tartler U, Wolf R, Arenberger P, Benninghoff B, Ruzicka T, Hengge UR, Walz M. Gene expression in actinic keratoses: pharmacological modulation by imiquimod. Br J Dermatol 2004; 151(6): 1150-9.
16. Fujisawa H, Kondo S, Wang B, Shivji GM, Souder DN. The expression and modulation of IFN-alpha and IFN-beta in human keratinocytes. J Interferon Cytokine Res 1997; 17(12): 721-5.
17. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schon MP. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95(15): 1138-49.
18. Burns Jr. RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000; 94(1): 13-23.
19. Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005; 44(1): 14-9.
20. Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, Lee JH, Fox TL, Alomar A. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51 (4): 547-55.
21. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50(5): 714-21.
22. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50(5): 722-33.
23. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, Tebbs V, McRae S. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152(5): 939-47.
24. Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol 2004; 140(4): 404-6.
25. Oster-Schmidt C. Two cases of squamous cell carcinoma treated with topical imiquimod 5%. J Eur Acad Dermatol Venereol 2004; 18(1): 93-5.
26. Hengge UR, Schaller J. Imiquimod and squamous cell cancer. Arch Dermatol 2005; 141(6): 787-8.
27. Uhoda I, Quatresooz P, Pierard-Franchimont C, Pierard GE. Nudging epidermal field cancerogenesis by imiquimod. Dermatology 2003; 206(4): 357-60.